Death receptors: targets for cancer therapy (Q37660616)

21 August 2017

1 reference

title

Death receptors: targets for cancer therapy (English)

1 reference

21 August 2017

Zafar Mahmood

1

1 reference

PubMed ID

20026107

21 August 2017

Yogeshwer Shukla

series ordinal

2

1 reference

PubMed ID

20026107

21 August 2017

language of work or name

English

0 references

publication date

21 December 2009

1 reference

Experimental Cell Research

21 August 2017

1 reference

21 August 2017

316

1 reference

21 August 2017

6

1 reference

21 August 2017

887-899

1 reference

Receptor-mediated choreography of life and death.

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Death receptors: signaling and modulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Apoptosis and the maintenance of homoeostasis in the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Modularity in the TNF-receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Death domain receptors and their role in cell demise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

TRAIL and apoptosis induction by TNF-family death receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Protein-based therapeutic approaches targeting death receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Death receptors as targets for anti-cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Death receptor ligands, in particular TRAIL, to overcome drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

CD95's deadly mission in the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The TNF and TNF receptor superfamilies: integrating mammalian biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

A death-domain-containing receptor that mediates apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

DR3 regulates negative selection during thymocyte development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Identification and characterization of a new member of the TNF family that induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

TRAIL-induced signalling and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

DR5 knockout mice are compromised in radiation-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Identification and functional characterization of DR6, a novel death domain-containing TNF receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Ectodysplasin signaling in development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Mechanisms of ectodermal organogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Ectodysplasin is a collagenous trimeric type II membrane protein with a tumor necrosis factor-like domain and co-localizes with cytoskeletal structures at lateral and apical surfaces of cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Ectodysplasin is released by proteolytic shedding and binds to the EDAR protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The anhidrotic ectodermal dysplasia gene (EDA) undergoes alternative splicing and encodes ectodysplasin-A with deletion mutations in collagenous repeats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Role of TRAF3 and -6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Stimulation of ectodermal organ development by Ectodysplasin-A1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Ectodysplasin A1 promotes placodal cell fate during early morphogenesis of ectodermal appendages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Ectodysplasin regulates pattern formation in the mammalian hair coat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth Factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The CD95(APO-1/Fas) DISC and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

7 January 2021

Death receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Interdimer processing mechanism of procaspase-8 activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Two CD95 (APO-1/Fas) signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The Bcl-2-regulated apoptotic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Death receptors couple to both cell proliferation and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Barriers to effective TRAIL-targeted therapy of malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Thymineless death in colon carcinoma cells is mediated via fas signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Gene transfer of Fas ligand induces tumor regression in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The potential of TRAIL for cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The prognostic value of TRAIL and its death receptors in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Sensitization of human colon cancer cells to TRAIL-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Apoptosis induced by death receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.12.011

10.1016/J.YEXCR.2009.12.011

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

20026107